Article Details

Conversation with The Cancer Letter BMS's Saha: We're at the start of defining new endpoints ...

Retrieved on: 2018-05-04 07:03:37

Tags for this article:

Click the tags to see associated articles and topics

Conversation with The Cancer Letter BMS's Saha: We're at the start of defining new endpoints .... View article details on hiswai:

Excerpt

<div>Bristol-Myers Squibb's three-year collaboration with <b>Flatiron Health</b> will focus on leveraging real-world data to improve the pharmaceutical company's regulatory submissions, demonstrate the economic value of BMS's cancer portfolio, and to study the predictive value of biomarkers. “Contemplating ...</div>

Article found on:

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up